High frequency of CD8 escape mutations in elite controllers as new obstacle for HIV cure

References

• Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387(6629):188–191.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362(9377):22–29.
   PubMed Web of Science ®Google Scholar
• Chun TW, Davey RT, Engel D, et al. Re-Emergence of HIV after stopping therapy. Nature. 1999;401(6756):874–875.
   PubMed Web of Science ®Google Scholar
• Chun TW, Engel D, Berrey MM, et al. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. PNAS. 1998;95(15):8869–8873.
   PubMed Web of Science ®Google Scholar
• Deeks SG. HIV: shock and kill. Nature. 2012;487(7408):439–440.
   PubMed Web of Science ®Google Scholar
• Archin NM, Kirchherr JL, Sung JA, et al. Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. J Clin Invest. 2017;127(8):3126–3135.
   PubMed Web of Science ®Google Scholar
• Elliott JH, Wightman F, Solomon A, et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog. 2014;10(10):e1004473.
   PubMedGoogle Scholar
• Ho YC, Shan L, Hosmane NN, et al. Replication-Competent non-induced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. 2013 Oct 24;155(3):540–551.
   PubMed Web of Science ®Google Scholar
• Deng K, Pertea M, Rongvaux A, et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature. 2015;517(7534):381–385.
   PubMed Web of Science ®Google Scholar
• Autran B, Descours B, Avettand-Fenoel V, et al. Elite controls as a model of functional cure. Curr Opin HIV AIDS. 2011;6(3):181.
   PubMed Web of Science ®Google Scholar
• Okulicz JF, Marconi VC, Landrum ML, et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US department of defense HIV natural history study. J Infect Dis. 2009;200(11):1714.
   PubMed Web of Science ®Google Scholar
• Siliciano JD, Kajdas J, Finzi D, et al. Long-Term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003;9(6):727–728.
   PubMed Web of Science ®Google Scholar
• Miura T, Brumme CJ, Brockman MA, et al. HLA-Associated viral mutations are common in human immunodeficiency virus type 1 elite controllers. J Virol. 2009;83(7):3407–3412.
   PubMed Web of Science ®Google Scholar
• Bailey JR, Williams TM, Siliciano RF, et al. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med. 2006;203(5):1357–1369.
   PubMed Web of Science ®Google Scholar
• O’Connell KA, Hegarty RW, Siliciano RF, et al. Viral suppression of multiple escape mutants by de novo CD8+ T cell responses in a human immunodeficiency virus-1 infected elite suppressor. Retrovirology. 2011;8(1):63.
   PubMedGoogle Scholar
• Caetano DG, Heloise Côrtes F, Bello G, et al. Next generation sequencing analyses of the emergence and maintenance of mutations in CTL epitopes in HIV controllers with differential viremia control. Retrovirology. 2018;15(1):62.
   PubMedGoogle Scholar
• Monteiro Gomes ST, da Silva Graça Amoras E, Ribeiro Gomes E, et al. Immune escape mutations in HIV-1 controllers in the Brazilian Amazon region. BMC Infect Dis. 2020;20(1):546.
   PubMed Web of Science ®Google Scholar
• Bailey JR, Brennan TP, O’Connell KA, et al. Evidence of CD8+ T-cell-mediated selective pressure on human immunodeficiency virus type 1 nef in HLA-B*57+ elite suppressors. J Virol. 2009;83(1):88–97.
   PubMed Web of Science ®Google Scholar
• Roberts HE, Hurst J, Robinson N, et al. Structured observations reveal slow HIV-1 CTL escape. PLoS Genet. 2015;11(2):e1004914.
   PubMed Web of Science ®Google Scholar
• Hatano H, Delwart EL, Norris PJ, et al. Evidence for persistent low-level Viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol. 2009;83(1):329–335.
   PubMed Web of Science ®Google Scholar
• Liu Y, McNevin J, Cao J, et al. Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol. 2006;80(19):9519–9529.
   PubMed Web of Science ®Google Scholar
• Pohlmeyer CW, Buckheit RW, Siliciano RF, et al. CD8+ T cells from HLA-B*57 elite suppressors effectively suppress replication of HIV-1 escape mutants. Retrovirology. 2013;10(1):152.
   PubMedGoogle Scholar
• Frahm N, Kiepiela P, Adams S, et al. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol. 2006;7(2):173–178.
   PubMed Web of Science ®Google Scholar